Objective: Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), such as cetuximab (Cmab) and panitumumab (Pmab), exhibit antitumor activity and acceptable safety profiles in patients (pts) with metastatic colorectal cancer (mCRC).Despite the effectiveness of irinotecan-based chemotherapy combined with Cmab or Pmab in salvage-line therapy,no trials directly comparing these antibodies have been conducted.